Nail Paksoy

<p style="margin-left:0px;"><br /><strong>PROFESSIONAL EXPERIENCE</strong></p><p style="margin-left:0px;"><strong>2011-2012</strong><br /><i>Erzurum Koprukoyu State Hospital</i><br />Department: General Medicine</p><p style="margin-left:0px;"><strong>2012-2017</strong><br /><i>Istanbul University Cerrahpaşa Medical Faculty</i><br />Department: Internal Medicine</p><p style="margin-left:0px;"><strong>06/2017-10/2017</strong><br /><i>Istanbul Gaziosmanpasa Taksim Training and Research Hospital</i><br />Department: Internal Medicine</p><p style="margin-left:0px;"><strong>10/2017-11/2018</strong><br /><i>Istanbul University Istanbul Medical Faculty</i><br />Department: Allergy and Immunology Fellowship</p><p style="margin-left:0px;"><strong>2018/2022</strong><br /><i>Istanbul University Oncology Institute</i><br />Department: Medical Oncology Fellowship</p><p style="margin-left:0px;"><strong>2022-2023</strong><br /><i>Tekirdag City Hospital</i><br />Department: Medical Oncology Specialist</p><p style="margin-left:0px;"><strong>2023-present</strong><br /><i>Istanbul Medipol University Medipol Bahcelievler Private Hospital</i><br />Department: Medical Oncology Assoc. Prof.</p><p style="margin-left:0px;"> </p><p style="margin-left:0px;"><strong>EDUCATION</strong></p><p style="margin-left:0px;"><strong>2005-2011</strong><br /><i>Medical Education</i><br />Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey</p><p style="margin-left:0px;"><strong>2012-2017</strong><br /><i>Internal Medicine</i><br />Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey</p><p style="margin-left:0px;"><strong>2017-2018</strong><br /><i>Allergy-Immunology Fellowship</i><br />Istanbul University Istanbul Medical Faculty<br />Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey</p><p style="margin-left:0px;"><strong>2018-2022</strong><br /><i>Medical Oncology Fellowship</i><br />Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey</p><p style="margin-left:0px;"><strong>2022</strong><br /><i>ESMO Board Certification in Medical Oncology</i><br />10th September 2022 in Paris, France.</p><p style="margin-left:0px;"><strong>2023</strong><br /><i>Medical Oncology Assoc. Prof.</i><br />Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey</p><p style="margin-left:0px;"> </p><p style="margin-left:0px;"><span style="color:rgb(15,15,15);"><strong>INTERNATIONAL CLINICAL TRIALS:</strong></span></p><p style="margin-left:0px;"><strong>1. Astefania - ROCHE</strong></p><ul><li><i>Title:</i> A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy</li><li><i>Role:</i> Subinvestigator</li></ul><p style="margin-left:0px;"><strong>2. PFİZER</strong></p><ul><li><i>Title:</i> A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC</li><li><i>Role:</i> Subinvestigator</li></ul><p style="margin-left:0px;"><strong>3. RECITE - AMGEN</strong></p><ul><li><i>Title:</i> Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer</li><li><i>Role:</i> Subinvestigator</li></ul><p style="margin-left:0px;"><strong>4. NAVIGATE - BAYER</strong></p><ul><li><i>Title:</i> A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors</li><li><i>Role:</i> Subinvestigator</li></ul><p style="margin-left:0px;"><strong>5. RUBY - Tesaro (PRA)</strong></p><ul><li><i>Title:</i> A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer</li><li><i>Role:</i> Subinvestigator</li></ul><p style="margin-left:0px;"><strong>6. ENGOT-ov43/GOG-3036 - MSD</strong></p><ul><li><i>Title:</i> Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)</li><li><i>Role:</i> Subinvestigator</li></ul><p style="margin-left:0px;"><strong>7. ASTRA ZENECA</strong></p><ul><li><i>Title:</i> To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.</li><li><i>Role:</i> Subinvestigator</li></ul><p style="margin-left:0px;"><strong>8. ROSY-O - ASTRA ZENECA</strong></p><ul><li><i>Title:</i> Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib</li><li><i>Role:</i> Subinvestigator</li><li> </li></ul><p style="margin-left:0px;"><strong>INTERNATIONAL PUBLICATIONS</strong></p><p style="margin-left:0px;">I. <strong>Published journal articles indexed by SCI, SSCI, and AHCI</strong></p><p style="margin-left:0px;"><strong>Weekly Paclitaxel in Classic Kaposi Sarcoma</strong></p><ul><li><i>Authors:</i> Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., &amp; Aydiner, A.</li><li><i>Journal:</i> Medicine, 102(5)</li></ul><p style="margin-left:0px;"><strong>Carboplatin Desensitization in Ovarian Carcinoma</strong></p><ul><li><i>Authors:</i> Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., &amp; Aydiner, A.</li><li><i>Journal:</i> Medicine, 101(45), e31726</li></ul><p style="margin-left:0px;"><strong>High-Dose Chemotherapy for Ewing’s Sarcoma</strong></p><ul><li><i>Authors:</i> Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., &amp; Başaran, M.</li><li><i>Journal:</i> Medicine, 101(49), e32213</li></ul><p style="margin-left:0px;"><strong>Multidrug Refractory TFE3(+) Renal Cell Carcinoma</strong></p><ul><li><i>Authors:</i> Paksoy, Nail, et al.</li><li><i>Journal:</i> Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221</li></ul><p style="margin-left:0px;"><strong>Crizotinib Efficacy in NSCLC with MET Alterations</strong></p><ul><li><i>Authors:</i> Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... &amp; Demirkazik, A.</li><li><i>Journal:</i> Medicine, 101(50), e32368</li></ul><p style="margin-left:0px;"><strong>Clinicopathological Features in ALK Mutant NSCLC</strong></p><ul><li><i>Authors:</i> Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... &amp; Aydiner, A.</li><li><i>Journal:</i> Medicine, 101(34)</li></ul><p style="margin-left:0px;"><strong>PSMA-Based Tumor Burden in Prostate Cancer</strong></p><ul><li><i>Authors:</i> HAS SIMSEK, Duygu, et al.</li><li><i>Journal:</i> Annals of Nuclear Medicine, 2021, 35.6: 680-690</li></ul><p style="margin-left:0px;"><strong>Atezolizumab in Metastatic Urothelial Carcinoma</strong></p><ul><li><i>Authors:</i> TURAL, Deniz, et al.</li><li><i>Journal:</i> European Urology Focus, 2021, 7.5: 1061-1066</li></ul><p style="margin-left:0px;"><strong>Pulmonary Sarcomatoid Carcinoma</strong></p><ul><li><i>Authors:</i> FERHATOGLU, Ferhat, et al.</li><li><i>Journal:</i> Oncology Research and Treatment, 2021, 44.11: 590-601</li></ul><p style="margin-left:0px;"><strong>Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma</strong></p><ul><li><i>Authors:</i> TURAL, Deniz, et al.</li><li><i>Journal:</i> International Journal of Clinical Oncology, 2021, 26.8: 1506-1513</li></ul><p style="margin-left:0px;"><strong>Atezolizumab with Chemotherapy in Small Cell Lung Cancer</strong></p><ul><li><i>Authors:</i> GÜRBÜZ, Mustafa, et al.</li><li><i>Journal:</i> Journal of Cancer Research and Clinical Oncology, 2022, 1-9</li></ul><p style="margin-left:0px;"><strong>FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer</strong></p><ul><li><i>Authors:</i> AY, Seval, et al.</li><li><i>Journal:</i> Journal of Chemotherapy, 2022, 1-7</li></ul><p style="margin-left:0px;"><strong>Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients</strong></p><ul><li><i>Authors:</i> CIL, Ibrahim, et al.</li><li><i>Journal:</i> Tumori Journal, 2022, 108.1: 19-25</li></ul><p style="margin-left:0px;"><strong>Real-Life Efficacy of Osimertinib in Advanced NSCLC</strong></p><ul><li><i>Authors:</i> HIZAL, Mutlu, et al.</li><li><i>Journal:</i> Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508</li></ul><p style="margin-left:0px;"><strong>ALK-Positive Cells Percentage and Alectinib Efficacy</strong></p><ul><li><i>Authors:</i> Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... &amp; Şendur, M. A. N.</li><li><i>Journal:</i> Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148</li></ul><p style="margin-left:0px;"><strong>Real-World Data on Alectinib in ALK-Positive NSCLC</strong></p><ul><li><i>Authors:</i> Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... &amp; Şendur, M. A. N.</li><li><i>Journal:</i> Future Oncology, 18(23), 2573-2582</li></ul><p style="margin-left:0px;"><strong>Prognostic Factors in Metastatic RCC with T790M Mutation</strong></p><ul><li><i>Authors:</i> Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., &amp; Basaran, M.</li><li><i>Journal:</i> Journal of Cancer Research and Therapeutics</li></ul><p style="margin-left:0px;"><strong>FLOT Regimen in Metastatic Gastric Cancer</strong></p><ul><li><i>Authors:</i> Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., &amp; Karabulut, S.</li><li><i>Journal:</i> Journal of Cancer Research and Therapeutics</li></ul><p style="margin-left:0px;"><strong>Desensitization Protocol in Lenalidomide Hypersensitivity Reactions</strong></p><ul><li><i>Authors:</i> DEMIR, Semra, et al.</li><li><i>Journal:</i> Annals of Allergy, Asthma &amp; Immunology, 2019, 123.4: 394-397</li></ul><p style="margin-left:0px;"><strong>Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity</strong></p><ul><li><i>Authors:</i> ÖZDEMIR, Seçil Kepil, et al.</li><li><i>Journal:</i> Allergy, 2019, 74.6: 1187-1190</li></ul><p style="margin-left:0px;"><strong>Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors</strong></p><ul><li><i>Authors:</i> Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... &amp; Sağlam, S.</li><li><i>Journal:</i> The Oncologist, oyad257</li></ul><p style="margin-left:0px;"><strong>Subsequent Treatments in Hormone-Positive Breast Cancer Progression</strong></p><ul><li><i>Authors:</i> Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... &amp; Hacıbekiroğlu, İ.</li><li><i>Journal:</i> BMC cancer, 23(1), 192</li></ul><p style="margin-left:0px;"><strong>Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer</strong></p><ul><li><i>Authors:</i> Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., &amp; Aydiner, A.</li><li><i>Journal:</i> Scientific Reports, 13(1), 8779</li></ul><p style="margin-left:0px;"><strong>Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer</strong></p><ul><li><i>Authors:</i> Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... &amp; Aydiner, A.</li><li><i>Journal:</i> Journal of Cancer Research and Clinical Oncology, 1-9</li></ul><p style="margin-left:0px;"><strong>Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer</strong></p><ul><li><i>Authors:</i> Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., &amp; Aydıner, A.</li><li><i>Journal:</i> European Journal of Breast Health, 19(2), 128</li></ul><p style="margin-left:0px;"><strong>Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer</strong></p><ul><li><i>Authors:</i> Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... &amp; Nahit Sendur, M. A.</li><li><i>Journal:</i> Future Oncology, 19(10), 727-736</li></ul><p style="margin-left:0px;"><strong>Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients</strong></p><ul><li><i>Authors:</i> Dogan, I., Paksoy, N., &amp; Basaran, M.</li><li><i>Journal:</i> Journal of Cancer Research and Therapeutics</li></ul><p style="margin-left:0px;"><strong>Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients</strong></p><ul><li><i>Authors:</i> Dogan, I., Paksoy, N., &amp; Basaran, M.</li><li><i>Journal:</i> Journal of Cancer Research and Therapeutics</li></ul><p style="margin-left:0px;"><strong>Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases</strong></p><ul><li><i>Authors:</i> Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., &amp; Basaran, M.</li><li><i>Journal:</i> Journal of Cancer Research and Therapeutics</li></ul><p style="margin-left:0px;"><strong>FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer</strong></p><ul><li><i>Authors:</i> Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., &amp; Karabulut, S.</li><li><i>Journal:</i> Journal of Cancer Research and Therapeutics</li></ul><p style="margin-left:0px;"><strong>Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer</strong></p><ul><li><i>Authors:</i> Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... &amp; Sendur, M. A. N.</li><li><i>Journal:</i> [Not specified]</li></ul><p style="margin-left:0px;"><strong>Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma</strong></p><ul><li><i>Authors:</i> Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., &amp; Aydiner, A.</li><li><i>Journal:</i> Medicine, 102(39), e35383</li></ul><p style="margin-left:0px;"><strong>Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma</strong></p><ul><li><i>Authors:</i> Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., &amp; Ekenel, M.</li><li><i>Journal:</i> Medicine, 102(41), e35245</li></ul><p style="margin-left:0px;"><strong>Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study</strong> - <i>Authors:</i> Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., &amp; Taştekin, D. - <i>Journal:</i> TURKISH JOURNAL OF ONCOLOGY, 1(1)</p><p style="margin-left:0px;"><strong>Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience</strong> - <i>Authors:</i> Paksoy, N., Trabulus, S., Seyahi, N., &amp; Altiparmak, M. R. - <i>Journal:</i> Namik Kemal Tip Dergisi, 11(1)</p><p style="margin-left:0px;"><strong>Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors</strong> - <i>Authors:</i> Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., &amp; Basaran, M.</p><p style="margin-left:0px;"><strong>Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer</strong> - <i>Authors:</i> Ak, Naziye, et al. - <i>Journal:</i> Journal of Oncological Sciences, 7.2: 42-49</p><p style="margin-left:0px;"><strong>Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma</strong> - <i>Authors:</i> Ak, Naziye, et al. - <i>Journal:</i> Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4</p><p style="margin-left:0px;"><strong>Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib</strong> - <i>Authors:</i> Ferhatoglu, F., Karabulut, S., Paksoy, N., &amp; Tastekin, D.</p><p style="margin-left:0px;"><strong>Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib</strong> - <i>Authors:</i> Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., &amp; Aydine, A. - <i>Journal:</i> TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY</p><p style="margin-left:0px;"><strong>Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors</strong> - <i>Authors:</i> Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., &amp; Aydıner, A. - <i>Journal:</i> Eurasian Journal of Pulmonology</p><p style="margin-left:0px;"><strong>Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study</strong> - <i>Authors:</i> Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... &amp; Saip, P. - <i>Journal:</i> Eurasian Journal of Medical Investigation, 7(2)</p><p style="margin-left:0px;"><strong>Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital</strong> - <i>Authors:</i> Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... &amp; Vatansever, S. - <i>Journal:</i> Turk Onkoloji Dergisi, 38(1)</p><p style="margin-left:0px;"><strong>Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center</strong> - <i>Authors:</i> Ferhatoglu, F., Paksoy, N., &amp; Başaran, M. - <i>Journal:</i> Namik Kemal Tip Dergisi, 10(4)</p><p style="margin-left:0px;"><strong>Evaluation of clinical features and risk factors related to late recurrence (&gt; 5 years) in patients with breast cancer</strong> - <i>Authors:</i> Ferhatoglu, F., Aydiner, A., &amp; Paksoy, N. - <i>Journal:</i> Journal of Surgery &amp; Medicine (JOSAM), 6(12)</p><p style="margin-left:0px;"><strong>Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye</strong></p><p style="margin-left:0px;"> </p><p><strong>Thesis:</strong></p><p>Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)</p><p><strong>International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)</strong></p><p style="margin-left:0px;"><strong>Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination</strong></p><ul><li><i>Authors:</i> Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., &amp; Aydiner, A. (2022)</li></ul><p style="margin-left:0px;"><strong>Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study</strong></p><ul><li><i>Authors:</i> Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... &amp; Gulmez, A. (2022)</li></ul><p style="margin-left:0px;"><strong>Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer</strong></p><ul><li><i>Authors:</i> Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... &amp; Aydiner, A. (2021)</li></ul><p style="margin-left:0px;"><strong>Efficacy of temozolomide in pretreated patients with metastatic sarcoma</strong></p><ul><li><i>Authors:</i> Paksoy, N., Dogan, I., Ekenel, M., &amp; Basaran, M. (2021)</li></ul><p style="margin-left:0px;"><strong>Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors</strong></p><ul><li><i>Authors:</i> Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., &amp; Basaran, M. (2021)</li></ul><p style="margin-left:0px;"><strong>Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma</strong></p><ul><li><i>Authors:</i> Paksoy, N., Dogan, I., Ekenel, M., &amp; Basaran, M. (2021)</li></ul><p style="margin-left:0px;"><strong>Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases</strong></p><ul><li><i>Authors:</i> Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., &amp; Basaran, M. (2021)</li></ul><p style="margin-left:0px;"><strong>Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma</strong></p><ul><li><i>Authors:</i> Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... &amp; Erman, M. (2021)</li></ul><p style="margin-left:0px;"><strong>Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study</strong></p><ul><li><i>Authors:</i> Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... &amp; Paydas, S. (2023)</li></ul><p style="margin-left:0px;"><strong>Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences</strong></p><ul><li><i>Authors:</i> Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... &amp; Kılıçkap, S. (2021)</li></ul><p> </p><p> </p>